Crossmark

Targeted Silencing of NRF2 by rituximab-conjugated nanoparticles increases the sensitivity of chronic lymphoblastic leukemia cells to Cyclophosphamide

Crossref DOI link: https://doi.org/10.1186/s12964-023-01213-1

Published Online: 2023-08-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Khodakarami, Atefeh

Kashani, Mahsa Afsari

Nazer, Atefeh

Kheshti, Armin Mahmoudsalehi

Rashidi, Bentolhoda

Karpisheh, Vahid

Masjedi, Ali

Abolhasani, Shiva

Izadi, Sepideh

Bagherifar, Rafieh

Hejazian, Seyyed Sina

Mohammadi, Hamed

Movassaghpour, AliAkbar

Feizi, Abbas Ali Hosseinpour

Hojjat-Farsangi, Mohammad

Jadidi-Niaragh, Farhad
License Information

Text and Data Mining valid from 2023-08-01

Version of Record valid from 2023-08-01
More Information

Article History

Received: 1 January 2023

Accepted: 1 July 2023

First Online: 1 August 2023

Declarations

:

: The following study was approved by Tabriz University of Medical Sciences (ethic code: IR.TBZMED.REC.1400.053). Informed consent was obained prior to sampling.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below